FDA
-
-
-
-
-
-
-
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
-
-
-
-
-
-
-
INmune Bio to present Phase 2 imaging data for XPro at AAIC 2026
-
-
-
-
-
-
-
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
-
-
-
-
-
-
-
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
-
-
-
-
-
-
-
INmune Bio expands CORDStrom platform collaboration with Anthony Nolan
-
-
-
-
-
-
-
INmune Bio reports 2025 financial results, plans regulatory filings
-
-
-
-
-
-
-
INmune Bio receives FDA alignment on phase 2b/3 trial design for alzheimer's drug
-
330,180 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

